Filter Results

Locations

Study status

(for at least one location)

Gender

Age

Healthy Volunteer

What is this?
A volunteer subject with no known significant health problems who participates in research to test a new drug, device or intervention. These volunteers are recruited to serve as controls for patient groups. Healthy volunteers receive the same test, procedure, or drug the patient group receives.

Study phase

What is this?
During the early phases (phases 1 and 2), researchers assess safety, side effects, optimal dosages and risks/benefits. In the later phase (phase 3), researchers study whether the treatment works better than the current standard therapy. They also compare the safety of the new treatment with that of current treatments. Phase 3 trials include large numbers of people to make sure that the result is valid. There are also less common very early (phase 0) and later (phase 4) phases. Phase 0 trials are small trials that help researchers decide if a new agent should be tested in a phase 1 trial. Phase 4 trials look at long-term safety and effectiveness, after a new treatment has been approved and is on the market.

Search Results 21-30 of 38 for multiple myeloma

  • Results filtered:
  • Study status: Open/Status Unknown
Edit search filters
  1. A Study To Evaluate VSV-hIFNbeta-NIS To Treat Patients With Relapsed/Refractory Multiple Myleoma, Acute Myeloid Leukemia, Or T-cell Lymphoma

    Scottsdale/Phoenix, AZ, Rochester, MN

  2. MC230818 Understanding the mechanisms of clonal and non-clonal cytopenia following CAR-T therapy (MC230818)

    Albert Lea, MN, Scottsdale/Phoenix, AZ, Eau Claire, WI, Jacksonville, FL, La Crosse, WI, Mankato, MN, Rochester, MN

  3. Inobrodib, Pomalidomide And Dexamethasone In Relapsed Or Refractory Multiple Myeloma

    Scottsdale/Phoenix, AZ, Jacksonville, FL, Rochester, MN

  4. Horizon Two Adaptive Platform Study In High Risk Newly Diagnosed Multiple Myeloma

    Rochester, MN

  5. Study Of SIM0500 Alone In Participants With Relapsed Or Refractory Multiple Myeloma

    Scottsdale/Phoenix, AZ, Jacksonville, FL, Rochester, MN

  6. A Study To Evaluate The Efficacy Of Cemsidomide + Dexamethasone In Participants With Relapsed/Refractory Multiple Myeloma

    Scottsdale/Phoenix, AZ, Jacksonville, FL, Rochester, MN

  7. A Study Comparing JNJ-79635322 And Teclistamab In Participants With Relapsed Or Refractory Multiple Myeloma

    Scottsdale/Phoenix, AZ, Jacksonville, FL, Rochester, MN

  8. A Study Comparing JNJ-79635322 And An Anti-B-cell Maturation Antigen (BCMA)xCD3 Bispecific Antibody In Participants With Relapsed Or Refractory Multiple Myeloma

    Scottsdale/Phoenix, AZ, Jacksonville, FL, Rochester, MN

  9. A Study Of Belantamab Mafodotin Administered In Combination With Lenalidomide And Dexamethasone (BRd) Versus Daratumumab, Lenalidomide, And Dexamethasone (DRd) In Participants With Newly Diagnosed Multiple Myeloma (NDMM) Who Are Ineligible For Autologous Stem Cell Transplantation (TI-NDMM)

    Scottsdale/Phoenix, AZ

  10. A Study To Assess A Change In Disease Activity And Adverse Events Of Intravenous Etentamig And Daratumumab (Etentamig+D) Compared To Daratumumab, Lenalidomide, And Dexamethasone (DRd) In Adult Participants With Newly Diagnosed Multiple Myeloma Not Eligible For Transplant

    Scottsdale/Phoenix, AZ, Rochester, MN

.

Mayo Clinic Footer